Y-320, a novel immune-modulator, sensitizes multidrug-resistant tumors to chemotherapy.
In conclusion, our results confirm that Y-320 is a promising chemotherapy sensitizer for the first time. The co-administration of Y-320 and chemotherapeutic agents might be an effective and low-toxicity chemotherapeutic regime for the MDR tumor patients.
PMID: 32194903 [PubMed]
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
More News: Arthritis | Autoimmune Disease | Cancer | Cancer & Oncology | Chemotherapy | Multidrug Resistance | Research | Rheumatoid Arthritis | Rheumatology | Study | Toxicology